Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

NCT05151458 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-12-14

No results posted yet for this study

Summary

Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and plasma cells.

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-29
Primary Completion
2022-11-29
Completion
2022-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05151458 on ClinicalTrials.gov